MTOR and mantle cell lymphoma: None of the dual mTORC1/2 inhibitors have reached the clinical trial phase, but recently designed clinical trials have incorporated mTOR inhibitors in their treatment regimen for relapse/refractory MCL cases (Tables 2, 3).